Objective: To investigate the relative bioavailability and bioequivalence, in fasting and fed conditions, of repeated doses of two omeprazole enteric-coated formulations in healthy volunteers. Proton ...

Bionxt Solutions is accelerating development of its flagship project, moving a Cladribin-based dissolvable film toward human clinical trials following compellin ...

NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ...

NEW YORK and MELBOURNE, Australia, July 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing ...

The US Food and Drug Administration (FDA) released a draft guidance on April 3 providing recommendations to sponsors and testing sites on data integrity for bioavailability and bioequivalence (BA/BE) ...

MIAMI, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that the clinical trial of the Company’s proprietary Tadalafil and ...

DUBLIN--(BUSINESS WIRE)-- Maven Semantic (http://www.mavensemantic.com) announces updates to their Bioavailability / Bioequivalence database. The new database is now ...

You have full access to this article via your institution. These results have led the Endocrine Society, the American Association of Clinical Endocrinologists, and the American Thyroid Association ...

Detailed price information for Bionxt Solutions Inc. (BNXT-CN) from The Globe and Mail including charting and trades.

Inhibition of gastric acid secretion by omeprazole increases with continuous drug administration and reaches a plateau after about 4 days of therapy. [19] In the present study, the relative ...